Cancer

Salix Pharmaceuticals Partners with Bellamy Young

Bellamy Young is Moving Past Stigma as She Speaks Candidly about Her Father's Struggle with Chronic Liver Disease/Cirrhosis and Resulting…

6 months ago

BriaCell Partners with New York Cancer & Blood Specialists (NYCBS) for Pivotal Phase 3 Study of Bria-IMT™ in Advanced Breast Cancer

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT)…

6 months ago

A New Publication Highlights the Use of cResponse in the Assessment of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer

A recent publication in "Cancer Discovery" reviewed Germline BRCA-associated pancreatic ductal adenocarcinoma (glBRCA PDAC) spectrum of responses to platinum and…

6 months ago

Massive Bio Pioneers Clinical Trial Recruitment Innovation with Strategic Support from Evernorth Health, Inc.

Elevating Global Patient Access to Clinical Trials through Revolutionary Collaboration and Advanced AI-Driven TechnologiesNEW YORK--(BUSINESS WIRE)--Massive Bio Inc., a trailblazing…

6 months ago

Delphinus Medical Technologies Appoints Scott A. White as New CEO

Long-time CEO Mark J. Forchette to retireNOVI, Mich.--(BUSINESS WIRE)--#SoftVue--Delphinus Medical Technologies, a pioneering medical imaging company that developed the SoftVue™…

6 months ago

Carebox Welcomes THANC to the Carebox Connect Network

THANC Guide resource center for thyroid, head and neck cancer patients will now feature Carebox Connect for clinical trial search…

6 months ago

BriaCell Initiates Pivotal Phase 3 Study of Bria-IMT™ in Advanced Metastatic Breast Cancer

The randomized pivotal Phase 3 study is expected to enroll a total of 354 patients in either Bria-IMT™ combination or…

6 months ago

Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma

Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent…

6 months ago

Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose…

6 months ago

Femasys Inc. MDSAP Surveillance Audit Successfully Completed

– Femasys demonstrates compliance with harmonized regulatory requirements for Australia, Brazil, Japan, Canada and the USA – – Femasys is committed…

6 months ago